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Abstract This review will make familiar with new con-
cepts in ovarian cancer and their impact on radiological
practice. Disseminated peritoneal spread and ascites are
typical of the most common (70–80 %) cancer type, high-
grade serous ovarian cancer. Other cancer subtypes differ
in origin, precursors, and imaging features. Expert sonog-
raphy allows excellent risk assessment in adnexal masses.
Owing to its high specificity, complementary MRI
improves characterization of indeterminate lesions. Major
changes in the new FIGO staging classification include
fusion of fallopian tube and primary ovarian cancer and the
subcategory stage IIIA1 for retroperitoneal lymph node
metastases only. Inguinal lymph nodes, cardiophrenic
lymph nodes, and umbilical metastases are classified as
distant metastases (stage IVB). In multidisciplinary con-
ferences (MDC), CT has been used to predict the success of
cytoreductive surgery. Resectability criteria have to be
specified and agreed on in MDC. Limitations in detection
of metastases may be overcome using advanced MRI
techniques.
Keywords Ovarian neoplasm/diagnosis  Neoplasm
staging  Ovarian neoplasm/therapy  Diagnostic imaging 
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Introduction
From a clinical perspective, ovarian cancer remains a
major challenge. Despite advances in medicine over the
past decades, only minor improvement in 5-year overall
survival has been achieved in patients diagnosed with
advanced epithelial ovarian cancer [1]. This cancer is the
most lethal among the pelvic cancers, and cancer-asso-
ciated mortality is as high as for cervical cancer and
uterine cancer combined [2]. One of the reasons is its late
diagnosis with more than 60 % of patients presenting
already with metastatic spread beyond the pelvis. In this
scenario, episodes of tumor recurrence will develop, fol-
lowed by chemo resistance, and subsequently these
patients will succumb to their disease [3•]. Increased
understanding of the molecular biology of ovarian cancer
opens new perspectives, and targeted therapies are
emerging [4]. Moreover, gene abnormalities have been
identified in different cancers subtypes, which will pro-
vide the basis for a personalized management in patients
with ovarian cancer [3•].
This review will focus on the most common cancer type,
epithelial ovarian cancer (EOC). The other primaries
including germ cell and sex-cord stromal cell ovarian
cancer are extremely rare (\5 %) and differ in many
aspects, but share the same staging classification with EOC
[5, 6]. An update of recent advances regarding EOC will be
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provided with special emphasis on their impact on clinical
radiological practice.
New Insights in Ovarian Cancer Biology
The concept of ovarian cancer as a single disease has been
revised. Epithelial ovarian cancer is now understood as a
subsumption of diverse cancer entities that vary signifi-
cantly clinically as well as pathologically and on a
molecular level [7–9]. It comprises the following main
cancer subtypes:
• high-grade serous,
• low-grade serous,
• endometrioid,
• clear cell and
• mucinous ovarian cancer [6, 11].
Differentiation of these subtypes is pivotal with regards
to several aspects, such as biomarkers, precursor lesions,
clinical presentation at diagnosis, prognosis, and response
to treatment [5–11] (Table 1). Furthermore, considerable
heterogeneity even within the same epithelial ovarian
cancer subtype has been identified on a macroscopic and
molecular level. This has also been attributed to the ded-
ifferentiation within different implants of the same primary
and thus the problem of tumor recurrence after initial
response to therapy [3, 12].
From the radiological perspective, it is pivotal to
understand that these subtypes of EOC may manifest with
distinct radio-morphology of the primary ovarian mass and
peritoneal metastatic traits at diagnosis may differ
(Table 1) [7, 13]. The two serous cancer subtypes [high-
grade (HGSC) and low-grade serous cancer (LGSC)] are
fundamentally distinct neoplasms including molecular
pathogenesis, their response to chemotherapy as well as
prognosis [11]. Typical for HGSC is diffuse peritoneal
dissemination at diagnosis, usually presenting with large
amounts of ascites and peritoneal deposits throughout the
abdominal cavity [13] (Fig. 1). Moreover, Vargas et al.
reported an association between patterns of spread on CT
imaging in different subtypes of HGSC based on the
classification of ovarian cancer (CLOVAR) gene signa-
tures. The mesenchymal CLOVAR subtype was found to
be significantly more often associated with both diffuse
mesenteric infiltration and peritoneal enhancement and
adverse survival than the other genetic subtypes [14].
High-grade serous epithelial ovarian cancer is promoted
by TP53 and BRCA1/2 mutations and seems to develop de
novo and within only several months [13]. Conversely,
low-grade serous ovarian cancer develops in a stepwise
fashion from serous cystadenoma to serous Borderline
cancer. In these tumors, KRAS and BRAF mutations are
frequently identified, rather than BRCA1/2 mutations as in
high-grade serous cancers [11]. The gradual malignant
degeneration from a benign precursor lesion and slow
growth is a feature that LGSC shares with the subtypes
Table 1 Clinico-pathological and radiological characteristics of ovarian cancer subtypes
Carcinoma
subtype
HG-serous LG-serous Mucinous Endometrioid Clear cell
Percentage (%) 70–80 \5 3 10 5–10
Gene mutations TP53, BRCA1/2 BRAF; KRAS KRAS PTEN;CTNNB-1 KRAS, PTEN, PIK3CA
Precursor STIC Serous cystadenoma
borderline tumor
Mucinous
cystadenoma
borderline
tumor
Endometriosis Endometriosis, clear cell
adenofibroma
Tumor
morphology
Cystic and solid;
solid; irregular
contour
Solid and cystic;
papillary projections;
Psammoma bodies;
Large, cystic or
solid; smooth
contour
Smooth contour; solid and
cystic; solid nodule in
endometrioma
Large, thick wall; cystic
with mural nodules
protruding into lumen
Uni- or bilateral Bilateral Bilateral Unilateral Unilateral Rarely bilateral
Dissemination Diffuse
abdominal
Abdominal Ovary Pelvic Pelvic
Platinum-based-
chemotherapy
response
High Intermediate Low High Low
Prognosis Poor Intermediate Good Good Intermediate
Adapted from references [3, 5, 11, 13]
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mucinous, endometrioid, and clear cell cancer. For the
latter two cancer types, endometriosis has been identified
as precursor [15].
High-grade serous ovarian cancer accounts for the vast
majority (70–80 %) of ovarian cancers. There is increasing
evidence that many of these cancers derive from tubal
intraepithelial cells. This so called ‘‘serous tubal intraep-
ithelial carcinoma’’ (STIC) theory proposes that high-grade
serous ovarian cancer, tubal cancer, and primary peritoneal
cancer share the common origin from serous tubal
intraepithelial cancer [8, 9, 16, 17]. BRCA1 and BRCA2
mutation carriers have a 30–50 % life-time risk of devel-
oping ovarian cancer, mainly high-grade serous cancers
[11]. Identification of these gene mutations, which occur in
approximately 10 % of HGSCs, is important, as these
patients have a better prognosis, and new therapeutic
options can be offered [18].
Prediction of Malignancy in Adnexal Masses
The clinical impact of defining whether an adnexal mass is
benign or malignant is enormous. If a newly detected
lesion carries a substantial risk of malignancy, treatment
should be performed in a specialist oncology center [19].
Women believed to have advanced ovarian cancer usually
require radical cytoreductive surgery followed by
chemotherapy or alternatively neoadjuvant chemotherapy
followed by interval debulking. Conversely, women with
benign adnexal masses may be either treated conserva-
tively or undergo simple resection by a general gynecolo-
gist [20]. Thus, predictive models have been developed to
triage women presenting with adnexal masses to an
appropriate treatment regimen [21•]. Findings of malig-
nancy are listed in Table 2. For pre-surgical assessment of
such an adnexal mass, transvaginal ultrasonography (US)
combined with Doppler techniques is the first-line and best
imaging technique. When a lesion is large or extends
beyond the field of view of transvaginal US, complemen-
tary transabdominal US should be performed according to
the 2013 American College of Radiology appropriateness
criteria [22]. MRI is usually considered as complementary
problem-solving modality [20]. Integration of additional
clinical features (e.g., menopausal status) and serum
biomarkers (CA-125) allow further risk stratification, e.g.,
as in the widely used risk of malignancy index (RMI).
The value of gray scale and color Doppler US has been
extensively analyzed by the International Ovarian Tumor
Analysis (IOTA) group. The pattern recognition of specific
ultrasound findings and assignment into categories of
diagnostic certainty of malignancy is well established [23].
The IOTA reported a sensitivity of 91 % and specificity of
96 % of malignancy for a lesion in the categories highly
and moderately confident to be malignant [23]. When
performed by highly trained clinicians in women, this
imaging technique was even equivalent to logistic regres-
sion models [24]. Various US-based approaches have been
created and validated to optimize the pre-surgical diagnosis
of adnexal tumors. These include scoring systems, rules
models, logistic regression mathematical models, and the
ADNEX model [21•, 25–28]. The IOTA ‘‘simple rules’’
assist in classifying adnexal masses as benign or malignant
by assigning 5 US characteristics to each category [21•,
Fig. 1 High-grade serous cancer FIGO stage IIIC with a bilateral
solid adnexal mass, enlarged retroperitoneal lymph nodes (arrow-
head), and large amounts of ascites and peritoneal implant (arrow) at
the right diaphragm
Table 2 Imaging criteria for malignancy
Size [4 cm
Morphology Complex solid and cystic
Solid enhancing component
Thick septations[3 mm
Papillary projections
Central necrosis
Vascularization Type 3 dynamic contrast curve
Additional findings Ascites
Lymph node enlargement
Peritoneal carcinomatosis
Organ invasion
Adapted from references [31, 40]
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26]. These rules have been extensively studied and allow
excellent prediction of malignancy (pooled sensitivity of
93 % and specificity of 95 %) [26]. In a meta-analysis from
2014 (analyzing 195 studies and 19 ultrasound risk mod-
els), the LR2 model and the simple rules model yielded
sensitivities of 88–95 and 89–95 %, respectively, and
specificity of 77–88 and 76–85 %, respectively [21•, 27].
The authors concluded that these models are currently
considered as best US-based models and strategies for use
in clinical practice [21•]. The IOTA ADNEX model, a
multiclass risk prediction model is designed to recognize
specific histopathological entities [21•, 25]. A prospective
multi-center study reported that the nine predictors of this
ADNEX model not only allow differentiation of benign
tumors from malignant tumors, but also enable catego-
rization in five types of adnexal tumors (benign; borderline;
stage I tumors; stage II-IV and metastatic tumors) [25].
However, it has to be mentioned that the exams were
performed by experienced professionals, and there was not
a central revision of pathology.
The ability to correctly characterize adnexal masses
using subjective assessment directly correlates with the
level of training/experience [21•, 24]. However, even with
expert status 5–20 % of masses will remain indeterminate
or difficult to classify [28]. These typically exhibit the
following sonographic features: large size, uni- or multi-
locular with solid aspects, irregular walls and papillary
projections, and multilocular cysts. The majority of these
lesions are nevertheless benign tumors, mostly cystadeno-
mas, cystadenofibromas, and fibromas [20]. In one study,
70 % of these lesions were benign and 16 % were invasive
cancers and 14 % borderline malignant tumors [28].
In the European Society of Urogenital Radiology
(ESUR) guidelines, MRI is being recommended as a
complementary tool in indeterminate US. An algorithmic
approach using basic and problem-solving sequences will
allow a confident diagnosis in the majority of cases and
thus contribute to avoiding unnecessary surgery [20]. A
systematic review confirmed the ability of MRI to confi-
dently diagnose benign lesions in masses that were inde-
terminate at US using conventional techniques [29].
However, combining conventional MRI with the functional
techniques diffusion-weighted imaging (DWI) and
dynamic contrast enhancement (DCE) will further improve
characterization of complex adnexal masses [30] (Fig. 2).
DWI alone for differentiation between benign and malig-
nant adnexal lesions is limited due to overlap of findings,
although it will reliably exclude malignancy in cases where
Fig. 2 Ovarian cancer in an
87-year-old patient. Large
inhomogeneous solid mass with
cystic and necrotic areas and
ascites in ultrasound (a) and
T2W MRI (b, arrows). Typical
findings supporting malignancy
include highly vascularized
solid areas (c) with restricted
diffusion (d)
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no high signal is identified within a solid mass on high
b-value images [30, 31, 32•, 33, 34]. There is a reasonable
body of evidence that ADC quantification is not useful for
predicting benignity [33]. ADC entropy may have a
potential for characterization of malignancy. In one study,
analyzing 37 patients this technique showed significantly
higher accuracy than visual and quantitative ADC assess-
ment [35]. The technique of utmost importance for char-
acterization of complex adnexal masses is semi-
quantitative multiphase-dynamic contrast-enhanced MR
[36, 37]. For this technique, it has been shown that factors
related to tumor biological processes and neoangiogenesis
are determinants in the contrast uptake dynamics in
adnexal masses [38]. This technique is based on time-in-
tensity curves acquired of solid aspects of adnexal lesions
during multiphase-dynamic contrast-enhanced MRI.
Comparison of the enhancement pattern with that of
myometrium will allow to identify three types of
enhancement curves which correlate with benign, border-
line, and malignant lesions [39, 40•]. Type 1 time-intensity
curves are characterized by a gradual uptake of contrast
and has been more frequently encountered in benign than
borderline and never in malignant lesions. Type 2 time-
intensity curves, typical of borderline lesions, reflect an
early uptake of gadolinium (though later than myome-
trium) followed by a plateau. Type 3 time-intensity curves
are typical of malignant tumors, with an avid and early
contrast uptake, followed by a wash-out [39, 40•]. This
technique is also being used in the MRI ADNEX score
system, a standardized MR imaging and reporting system
for complex adnexal masses [40•]. The MRI ADNEX score
divides masses into five categories from score 1 corre-
sponding to no mass to score 5 that describes a probably
malignant mass. A feasibility study demonstrated excellent
reproducibility and interobserver agreement for various
degrees of expertise [39]. Currently, a prospective multi-
center validation study with more than 1600 patients is
being conducted by the ESUR, with data expected to be
published in 2016. Owing to false positive as well as false
negative findings, currently, PET/CT is of no advantage
over MRI for characterizing complex adnexal masses [41,
42].
Revised FIGO Classification and Potential Impact
on Radiological Interpretation
Ovarian cancer is surgically staged according to the FIGO
or TNM staging classification. The FIGO system, which is
most commonly used world-wide, has updated its classifi-
cation, effective from 2014 on. Of note, this classification
applies not only for EOC but also for sex-cord stromal and
germ cell malignancies [5, 43•]. A revision of the
classification seemed warranted in the light of new con-
cepts in ovarian cancer biology, including immunohisto-
chemical and molecular genetic analysis, overlap of
histopathological features, new prognostic factors, differ-
ences in chemotherapy response, and the need for new
treatment protocols [17, 43•, 44, 45].
In this new staging classification system, not only the
tumor stage should be documented, but also the histolog-
ical subtypes and grade.
Acknowledging the concept of a common origin of
high-grade serosal tumors from tubal cells, the most
important revision in the new staging classification
includes that now ovarian, fallopian, and primary peri-
toneal cancer are seen as one entity. The other major
change is the further subdivision of the stages III and IV.
The rationale for subcategorization of stage IIIA1 is that
according to evidence patients with isolated retroperitoneal
lymph node metastases have a better prognosis than those
who have extrapelvic peritoneal spread (now FIGO IIIB)
[45, 46]. The findings in the various FIGO stages are seen
in Table 3.
Imaging findings in CT and MRI have also been adapted
to the FIGO classification system [47, 48]. Thus, changes
and key features relevant for pre-therapeutic imaging are
highlighted in the following paragraph.
Of utmost importance is the understanding of merg-
ing of ovarian, fallopian tube, and primary peritoneal
cancer in staging. This results in major ramifications for
radiological reporting: fallopian tube and primary peri-
toneal cancers are no longer regarded as single entities
and thus they are no longer staged differently than
ovarian cancer [8, 9, 17]. In a malignant adnexal mass,
differentiation of fallopian from ovarian origin has often
been challenging. The classical findings of a sausage
like adnexal mass or fallopian tube distension and a
focal solid mass are only rarely visualized [49]. This
needs no longer to be differentiated, which will facili-
tate radiological reporting. The other major change is
that primary ovarian cancer no longer exists as a sepa-
rate entity. The findings previously indicative of this
disease, e.g., peritoneal metastases and normal ovaries
constitute now a subtype of ovarian cancer. Stage I
primary peritoneal cancer does not exist [17]. If it is
limited to the pelvis, it has to be classified as stage II,
but more often, it will present with stage III B or C with
ascites and spread outside the pelvis at diagnosis.
The new staging classification also leads to the clari-
fication of the lymph node status. Regional lymph nodes
in ovarian cancer remain pelvic (internal and external
iliac, obturator, and common iliac), presacral, and
paraaortic and paracaval nodes. Conversely, inguinal
lymph nodes are now considered as distant metastases
(IVB). In contrast to other sites, smaller lymph node
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thresholds are used to assess CLNM (cardiophrenic
lymph node metastases). A short axis cut-off of 5 mm has
been suggested as normal cardiophrenic lymph nodes size
[50]. A recent study reported 86 % positive predictive
value for histologically proven CLNM using a short axis
diameter of[7 mm in preoperative CT [51]. CLNM are
associated with peritoneal dissemination and are found in
approximately 30 % of advanced ovarian cancer [52].
These metastases occur typically in the anterior preperi-
cardiac region, more commonly on the right than on the
left side [51].
Stage IVA1 is characterized by pleural metastases pro-
ven either by positive cytology or biopsy. Stage IVB
characterizes parenchymal metastases in the abdomen or
extraabdominal lymph node metastases. Peritoneal
implants on surface of liver and spleen (stage IIIC) have to
be differentiated from parenchymal metastases in these
organs. Umbilical metastases, Sister Mary Joseph nodes,
are classified as metastases corresponding to stage IV B
[5]. Transmural bowel invasion with mucosal involvement
is also assigned to this category [5]. Conversely, rectum
invasion defined as stage IIB, since it represents spread
within the pelvis [5]. Quantification of ascites as small,
moderate, or large should be included in the report, because
it has shown to be related with survival [53].
Prediction of Resectability in Ovarian Cancer
Comprehensive staging laparotomy and cytoreductive
surgery followed by chemotherapy has been the standard of
care in newly diagnosed advanced ovarian cancer [17].
There is evidence that cytoreduction is associated with
increased survival in ovarian cancer. In the last years, the
ultimate goal of cytoreduction has continuously been
changed [17, 54]. Currently, a cut-off of 1 cm of residual
tumor size is defined as optimal cytoreduction [55]. How-
ever, a trend toward ultraradical surgery with complete
Table 3 FIGO classifications of ovarian cancer
FIGO stage Subcategory and findings
I A
Tumor one ovary or fallopian tube
B
Both ovaries or fallopian tubes
C
One or both ovaries or fallopian tubes and
C1: surgical spill
C2: capsule ruptured or tumor on surface
C3: malignant cells in ascites or peritoneal washings
II A
Extension/implants on uterus and/or ovaries and/or fallopian tubes
B
Extension to other pelvic intraperitoneal tissues
III A
A1 Positive retroperitoneal lymph nodes (LN) only
A1(i): metastasis B10 mm
A1(ii): metastasis[10 mm
A2 Microscopic extrapelvic peritoneal spread – LN
B
Peritoneal implants outside pelvis up to 2 cm ± retroperitoneal LN
C
Peritoneal implants outside pelvis[ 2 cm ± retroperitoneal LN; liver and/or spleen surface metastasis included
IV A
Pleural effusion with positive cytology
B
Parenchymal metastasis, metastasis to extraperitoneal organs, inguinal LN and LN outside abdominal cavity
Changes made to the version from 1998 are highlighted
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resection of all gross tumor deposits can be noted [55]. A
recent meta-analysis of 18 studies with more than 13,000
patients proved positive impact of complete cytoreduction
on median survival [56].
The best treatment for the advanced cancer stages IIIC
and IV has been a subject of ongoing debate and much
controversy over the last years [54, 57, 58]. Supporters of
neoadjuvant chemotherapy refer to cancer biology and to
the issue of high perioperative complications [54, 59].
Debulking rates differ significantly between different sites
and countries. Optimal cytoreduction broadly ranges from
15 to 85 %, with high-volume oncologic centers attaining
rates of 60–75 % [17, 60, 61]. To improve treatment
stratification, particularly to select patients amenable or not
for successful cytoreduction, various predictive tests have
been published. Major determinants include clinical risk
factors (e.g., age, performance status, obesity, and comor-
bidity), tumor markers (CA-125), and imaging, most
commonly CT [33, 60, 61]. However, the problem in the
preoperative assessment of resectability is that there is no
general accepted model and that reproducibility is a major
challenge due to different clinical practice. Other limita-
tions include complexity of scoring systems and prediction
models. Different resection rates are also attributed to
subjective assessment of resectability based on surgeons
experience and preference, on anesthesia support and dif-
ferent departmental policies [33].
Multidisciplinary consensus conferences (MDC) are the
platform to define individualized optimal treatment regi-
men. If a patient with ovarian cancer will benefit from
upfront surgery or rather from a neoadjuvant approach has
to be discussed in the context of patient-related factors and
surgical technical issues [33, 62•]. In this setting, the
accurate mapping of tumor burden and distribution of
disease by imaging plays a central role in treatment strat-
ification and will thus also influence patient outcome [47,
48, 62•]. Site, size, and distribution of metastases have
been used as radiological predictors for the outcome of
cytoreductive surgery. CT images need to be scrutinized
for subtle findings of peritoneal spread since these can
change treatment decision (Fig. 3). Various CT criteria
assessing different sites throughout the abdomen and CT
scores without and with the incorporation of CA-125 or
other clinical criteria have been proposed [33, 60, 61, 63,
64]. In the ESUR guidelines for staging ovarian cancer,
large disease ([2 cm) in the upper abdomen around the
liver and spleen, mesenteric deposits and lymph node
metastases above the renal hilum were summarized as sites
likely to be not optimally resectable [47] (Fig. 4). How-
ever, it was emphasized that resectability criteria may
differ from center to center, and that predictive parameters
have to be specified and agreed on in MDC [47]. Two
recent publications of high-volume tumor centers
addressed the value of CT for prediction of cytoreduction
in ovarian cancer. A multi-center prospective trial of two
major US cancer centers analyzed features to predict sub-
optimal cytoreduction. In 350 patients with surgically
treated ovarian cancer, three clinical and six radiological
criteria were significantly associated with suboptimal
debulking [60]. Borley et al. analyzed radiological pre-
dictors associated with debulking success and requirement
for bowel resection by logistic regression models. In their
study, the presence of lung metastases [7 mm, pleural
effusion, deposits [10 mm in size on large and small
bowel mesentery, and infrarenal paraaortic lymph node
Fig. 3 Subtle imaging findings indicative of advanced ovarian cancer
spread: ascites in omental bursa (a, asterisk) lymph node (b, arrow)
with a short axis diameter of[7 mm in the cardiophrenic fat above
the diaphragm. In all ovarian cancer staging exams, mesentery and
omentum should be scrutinized for band-like and reticular pattern (c,
arrows) presenting peritoneal spread
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metastases were associated with low success rate with
debulking [61]. Despite advanced surgical techniques in
both studies, bowel involvement was a major limitation for
optimal cytoreduction. Thus, signs of bowel and mesen-
teric involvement have to be carefully analyzed in CT, like
e.g., bowel wall thickening, adhesions, and mesenteric
tethering [14, 48]. Since small size (\5 mm) peritoneal
deposits are hard to see in CT, complementary laparoscopy
may play a role in the preoperative assessment of ovarian
cancer [57]. It seems that currently the role of PET/CT for
primary ovarian cancer staging is limited, as it is not
superior to CT alone, and treatment regimen is not changed
[41]. There is a paucity of data of advanced MRI tech-
niques for staging of ovarian cancer [33]. Low and Barone
used the peritoneal cancer index based on MRI/DWI and
DCE in 35 patients (5 with ovarian cancer) with peritoneal
carcinomatosis. Radiological–surgical correlation yielded a
high match of tumor sites [65]. Recently, these authors also
reported the superiority of this advanced MRI technique
compared to CT [66]. In a prospective comparative study
with surgery as standard of reference whole-body MRI
using DWI was superior to CT and to PET/CT in the
challenging assessment of bowel serosal and mesenteric
disease. Furthermore, metastases outside the abdomen
could be detected similarly to PET/CT [67•]. Conversely,
another comparative study found no significant differences
between MRI, CT, and PET/CT for staging. However,
PET/CT was more accurate for supradiaphragmatic
metastases [68].
Conclusion
Advances in immunohistochemistry and molecular genetics
are the basis of new concepts in ovarian cancer. Imaging is
integral in various aspects in assessing ovarian cancer. It is
not only used as a diagnostic tool but is also a major
determinant in triaging to personalized treatment. Sonogra-
phy is an excellent modality to predict malignancy in
adnexal masses and thus assists in reducing unnecessary
surgeries.
The use of functional MRI techniques is further
improving characterization of sonographically indetermi-
nate masses of which the vast majority will be benign. The
MRI ADNEX score provides standardized assessment and
reporting of complex adnexal masses.
In MDC, imaging plays a central role for treatment
stratification in ovarian cancer. It serves as a roadmap for
surgery and is one of the major predictors for successful
primary cytoreductive surgery. Currently, CT is the stan-
dard of care for staging patients with ovarian cancer.
However, MRI using functional techniques is emerging as
technique that may be able to overcome limitations of
staging CT.
The revised FIGO classification has introduced some
major changes radiologists have to be familiar with. This
includes the fusion of fallopian tube and primary ovarian
cancer, and new concepts regarding lymph node dissemi-
nation as well as distant metastases.
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Fig. 4 Excessive peritoneal
metastases in the upper
abdomen in high-grade serous
cancer. Sites as in the omental
bursa (arrow) and large deposits
along the gastrocolic ligament
(arrowhead) are findings
indicative of non-optimal
cytoreduction in most centers.
These may synonymously also
be termed as ‘‘difficult to
resect’’
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